


FORM-PTO-1390 (Rev. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 020600-280
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 09/341641
INTERNATIONAL APPLICATION NO. PCT/GB98/00130	INTERNATIONAL FILING DATE 15 January 1998	PRIORITY DATE CLAIMED 15 January 1997	
TITLE OF INVENTION NUCLEIC ACID SEQUENCING			
APPLICANT(S) FOR DO/EO/US Günter Schmidt, Andrew Hugin Thompson			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information:</p> <p>Notification of the Recording of a Change International Preliminary Examination Report Preliminary Amendment</p>			

U.S. APPLICATION NO. (If known, see 37 CFR 1.55) 09/341641		INTERNATIONAL APPLICATION NO. PCT/GB98/00130		ATTORNEY'S DOCKET NUMBER 020600-280	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$ 0.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	20-20 =	0	X \$18.00	\$ 0.00	
Independent Claims	2-3 =	0	X \$78.00	\$ 0.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 840.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$ 420.00	
SUBTOTAL =				\$ 420.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 420.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 420.00	
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>420.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Samuel C. Miller, III BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404			<div style="text-align: center;">  SIGNATURE </div> <div style="text-align: center;"> <u>Robin L. Teskin</u> NAME </div> <div style="text-align: center;"> <u>35,030</u> REGISTRATION NUMBER </div>		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Günter SCHMIDT et al)
Application No.: Unassigned) Group Art Unit: Unassigned
(Corresponds to PCT/GB98/00130))
International Filing Date: January 15, 1998)
For: NUCLEIC ACID SEQUENCING) Examiner: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the application as indicated.

In the Claims:

Kindly cancel original Claims 1-20 and substitute the following claims therefor:

--21. A method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising a plurality of single-stranded DNAs to be sequenced, each of which is present in a unique amount in the same reaction zone and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(b) contacting the DNA population with an array of hybridization probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and

the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended doublestranded portion which is incapable of ligation to further probes; and

- (c) removing all unligated probes; followed by the steps of:
- (d) cleaving the ligated probes to release each label;
- (e) recording the quantity of each label; and
- (f) activating the extended double-stranded portion to enable ligation thereto;

wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of each single-stranded DNA by determining the sequence of release of each label.

22. A method according to claim 21, wherein the array comprises a plurality of sub-arrays which together contain all the possible base sequences, and wherein each sub-array is contacted with the DNA population according to step (b), unligated probes are removed according to step (c), and these steps are repeated in a cycle before step (d) so that all of the subarrays contact the DNA population.

23. A method according to claim 21, wherein the target DNA population is obtained by sorting an initial DNA sample into sub-populations and selecting one of the subpopulations as the target DNA population.

24. A method according to claim 23, wherein the initial DNA sample is cut into fragments, each having a sticky end of known length and unknown sequence, which fragments are sorted into sub-populations according to their sticky end sequence.

25. A method according to claim 21, wherein each single-stranded DNA is immobilized at one end.

26. A method according to claim 21, wherein the label of each probe comprises a mass label, and the quantity of each label is recorded according to step (e) using mass spectrometry after release of the label in step (d).

27. A method according to claim 21, wherein the known base sequence is blocked at its 3'OH.

28. A method according to claim 27, wherein the step (d) of cleaving the ligated probes to release each label unblocks the 3'-OH of the extended double-stranded portion according to step (f).

29. A method according to claim 28, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence.
30. A method according to claim 21, wherein the base sequence of each probe is unphosphorylated at both 3' and 5' ends and step (f) comprises phosphorylating the 5'-OH of the extended double-stranded portion.
31. A method according to claim 21, wherein the predetermined length of the base sequence is from 2 to 6.
32. A method according to claim 31, wherein the predetermined length of the base sequence is 4.
33. A kit for sequencing DNA, which comprises an array of hybridization probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligating to each other.
34. A kit according to claim 33, wherein the known base sequence is blocked at its 3'-OH.

35. A kit according to claim 34, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence to prevent ligation thereto.

36. A kit according to claim 33, wherein the base sequence of each probe is unphosphorylated at both 3' and 5' ends.

37. A kit according to claim 33, wherein the label of each probe comprises a mass label.

38. A kit according to claim 33, wherein the predetermined length of the base sequence is from 2 to 6.

39. A kit according to claim 38, wherein the predetermined length of the base sequence is 4.

40. Use of a kit as defined in claim 33 for a method of sequencing DNA.--


REMARKS

The present Amendment is intended to eliminate the use of multiple dependency and to add an Abstract to the Specification.

The examination and allowance of the application respectfully are requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Robin L. Teskin
Registration No. 35,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: July 15, 1999

0544-099
66060-7497450

Applicant or Patentee: Günter Schmidt et al.

Application or Patent No.: 09/341,641

Filed or Issued: July 15, 1999

For: NUCLEIC ACID SEQUENCING

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. §§ 1.9(f) AND 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN BRAX GROUP LIMITED

ADDRESS OF CONCERN 13 Station Road

Cambridge, CB1 2JB, GB

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 1.21 for purposes of paying reduced fees under Sections 41(a) and 41(b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average, over the previous fiscal year of the concern, of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled NUCLEIC ACID SEQUENCING by inventor(s) Günter Schmidt and Andrew Hugin Thompson described in

- ☐ the specification filed herewith
☒ Application No. 09/341,641, filed July 15, 1999.
☐ Patent No. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern, or organization having rights to the invention is listed below,* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c), or by any concern that would not qualify as either a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27.)

NAME _____

ADDRESS _____

☐ individual ☐ small business concern ☐ nonprofit organization

NAME _____

ADDRESS _____

☐ individual ☐ small business concern ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee and any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b).)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dr. G. H. Schmidt

TITLE OF PERSON OTHER THAN OWNER Director

ADDRESS OF PERSON SIGNING HOUGHTON MANOR, HOUGHTON, CANES

SIGNATURE [Signature] DATE 27/8/99

8/PRTS

09/341641
80 Rec'd PCT/PTO 15 JUL 1999

WO 98/31831

PCT/GB98/00130

NUCLEIC ACID SEQUENCING

The present invention relates to a method for sequencing DNA and a kit for sequencing DNA.

Traditional methods for sequencing nucleic acid such as DNA frequently require biological sub-cloning hosts and vectors. Such traditional methods generally require gel chromatography to acquire sequence information. These traditional methods are therefore often complicated multi-stage processes which are both time-consuming and labour intensive.

PCT/US96/05245 discloses a method of nucleic acid sequencing based on an iterative process of duplex extension along a single-stranded template. Duplex extension is effected by ligating probes to a region of the template primed with an initialising oligonucleotide. The probes of the above method are labelled preferably with a fluorescent dye. The dye identifies a single base at the ligation site. The probes are prevented from uncontrolled extension by having removable blocking groups at one of their terminals.

PCT/GB95/00109 suggests a method of nucleic acid sequencing comprising sequentially extending a primer a pre-determined number of bases at a time, the added bases being complementary to the bases being sequenced. This is achieved by contacting the nucleic acid with a labelled adaptor, the label being specific to the base sequence of the adaptor. A population of adaptors is used having oligonucleotide sequences including all possible permutations for a pre-determined number of bases.

The present invention provides a method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising one or more single-stranded DNAs to be sequenced, each of which is present in a unique amount and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

09341641-090999

(2)

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of the or each single-stranded DNA by determining the sequence of release of each label.

In one embodiment the array comprises a plurality of sub-arrays which together contain all the possible base sequences, and wherein each sub-array is contacted with the DNA population according to step (b), unligated probes are removed according to step (c), and these steps are repeated in a cycle before step (d) so that all of the sub-arrays contact the DNA population. In this way, the array of hybridisation probes is presented to the DNA population in stages. For example, where the predetermined length of base sequence is 4 and the total number of possible base sequences is 256 (4^4), cross-hybridisation between complementary 4-mer in the array can be avoided by contacting the DNA population with a first sub-array of 128 probes and, after removing all unligated probes, contacting with a second sub-array of 128 probes.

(3)

The target DNA population may be obtained by sorting an initial DNA sample into sub-populations and selecting one of the sub-populations as the target DNA population. Thus, if the initial DNA sample is large its size can be reduced by the sorting step. In a preferred arrangement, the initial DNA sample is cut into fragments, each having a sticky end of known length and unknown sequence, typically a length of from 2 to 6, preferably about 4 bases. The fragments may be sorted into sub-populations according to their sticky end sequence. It is thought that a population or sub-population of at least 60 fragments can be sequenced in parallel with an acceptable error rate using a probe with a base sequence of 4 bases.

Preferably, each single-stranded DNA is immobilised, usually at one end, for example on a solid support such as a bead. This has the advantage that removal of unwanted material can take place in solution and separation of the labels from the probes is facilitated. Preferably, the target DNA is immobilised prior to step (b) on the solid phase support. The solid phase support may conveniently be attached to the primer.

The label may be any suitable label such as a fluorescent label, a radio label or a mass label. The identity of the label must be assignable to the respective base sequence so that identification of the label identifies the base sequence. In a preferred arrangement, the label of each probe comprises a mass label. Each mass label is uniquely identifiable in relation to every other mass label using a mass spectrometer. Typically each mass label has a distinct mass from every other mass label and preferably a single ionization state at the pH of analysis in a mass spectrometer. Each mass label preferably does not fragment in the mass spectrometer. Preferred mass labels do not interfere with the action of the ligase in the sequencing method or with any other of the molecular biology steps used in the invention.

Where the label is a mass label, the quantity of each label corresponding to the ligated hybridisation probe is recorded in

(4)

step (e) after release of the label in step (d). Where the label is a fluorescent label, step (e) may precede step (d) and the quantity of fluorescent label present on the ligated probe is recorded before the label is released.

In any one cycle of the method according to the invention it is essential that the base sequence of only one probe ligates to the double-stranded portion of each DNA. The base sequences of the probes of the array are therefore incapable of ligation to each other so that the extended double-stranded portion which is formed after ligation is incapable of ligation to further probes. In subsequent step (f), the extended double-stranded portion is activated to enable ligation thereto of a further probe in the next cycle. The base sequences may be incapable of ligation to each other either by requiring activation or by being blocked to prevent ligation thereto.

In one embodiment of the invention the known base sequence is blocked at its 3'-OH. According to this embodiment, primer extension sequencing takes place in the 5' to 3' direction. In another embodiment of the invention, the base sequences are capable of ligating to each other only when activated by phosphorylation. According to this embodiment, the base sequence of each probe is unphosphorylated at both 3' and 5' ends and activation step (f) comprises phosphorylating the 5'-OH of the extended double-stranded portion to enable ligation thereto.

Advantageously, the step (d) of cleaving the ligated probes to release each label unblocks the 3'-OH of the extended double-stranded portion according to step (f). In other words, step (d) and step (f) are one and the same. Preferably, the label of each probe is cleavably attached to the 3'-OH of the base sequence. Thus, cleaving the label from the probe unblocks the 3'-OH so as to allow a new hybridisation probe to ligate thereto in the next sequencing cycle.

Theoretically the predetermined length of the base sequence is

(5)

limited only by considerations of ligase fidelity. The longer the base sequence, the stronger the hybridisation will be between probe base sequence and single-stranded DNA. Thus, a length of 10 or 11 is thought to be about the maximum before ligase fidelity becomes unacceptable. However, practically speaking, sequences of this length would require too many unique labels to be useful, whereas, shorter base sequences require fewer unique labels. Preferably, the predetermined length of the base sequence is from 2 to 6, more preferably 4.

The invention further provides a kit for sequencing DNA, which comprises an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other. The array of hybridisation probes is preferably as defined above. The kit may further comprise instructions for use in a method of sequencing DNA. Use of the kit is therefore provided for a method of sequencing DNA, especially the method described above.

The invention will now be described in further detail by way of example only, with reference to the accompanying drawings, in which:-

FIGURES 1a and 1b show respectively first and second cycles of a preferred process according to the invention;

FIGURES 2a and 2b show respectively first and second cycles of an alternative process according to the invention;

FIGURE 3 shows typical adaptor molecules for use in the invention;

FIGURE 4 shows a preferred method of producing target DNA for sequencing in accordance with the invention;

FIGURE 5 shows a bar chart depicting the data for the first cycle of a 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase;

FIGURE 6 shows a bar chart depicting the data for the second

0034641-090999

(6)

cycle of the 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase; and

FIGURE 7 shows a bar chart depicting the data for the third cycle of the 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase.

Parallel sequencing of sorted populations of nucleic acids by primer extension sequencing:

This invention is a process that allows a heterogenous population of nucleic acid fragments, generated by various means, to be sequenced simultaneously. The process provides a novel strategy for sequencing genomic DNA that potentially could avoid the need for biological subcloning hosts and vectors.

The sequencing process described here allows one to produce nucleic acid fragment populations in a reproducible manner that can then be sorted into subsets and finally sequenced by an iterative process of ligation of probes to an immobilised single-stranded DNA molecule.

Generation of a mixed nucleic acid population	→ Sort molecules into subsets	→ Sequence molecules within subsets simultaneously
---	----------------------------------	--

Outline of sequencing process.

The sequencing steps use short single stranded oligonucleotides of a predetermined length to probe the sequence of single-stranded immobilised template nucleic acid fragments. Single-stranded regions adjacent to a primed region are determined by ligating the probe oligonucleotides to the primer and determining their identity on the basis of a tag carried by the oligonucleotides. The label determines the sequence of the oligonucleotide probes. Nucleic acid fragments are probed as heterogenous sets and sequence information is determined by measuring the quantity of label of correctly hybridised and ligated probes.

Sequencing can be performed in either a 5' to 3' format or in a 3' to 5' format. Uncontrolled extension in the 5' to 3' format

034464-00000

(7)

is prevented by reversibly blocking the 3' -OH at the terminus of the probes prior to addition of the probes to the extending primer. After ligation of probe to primer any unligated probe is washed away. The quantity of ligated probes is determined and the 3' terminus is unblocked to allow the next cycle of probing to be performed on the extended primer. In the 3' to 5' format, uncontrolled extension of the primer is controlled by using a phosphorylation step to add a triphosphate entity onto the extending primer's 5' -OH group. Probes are synthesised without any phosphate groups at the 5' terminus, so after each addition of probes to the extending primer, the 5' -OH must be phosphorylated to permit further extension.

The sequence of individual fragments is determined by comparing quantities of label for each type of probe in each cycle of the sequencing process with quantities derived in previous and subsequent cycles. The invention provides a method for analysing heterogenous sub-populations of nucleic acids without spatially resolving them. This is achieved by a signal acquisition and signal processing procedure that allows sequences to be identified on the basis of their relative quantities.

This process does not require traditional gel methods to acquire sequence information. Since the entire process takes place in solution and is an iterative process, the steps involved could be performed by a liquid-handling robot.

Sequencing large nucleic acid molecules:

It is not necessary to sequence an entire molecule at once to determine its sequence, which is fortunate as it is a practical impossibility, at the moment, to sequence molecules as large as chromosomes. It is calculated that any given sequence 17 bp long should be unique within the human genome. Similar calculations can be performed for genomes that are of different sizes. This consideration means that large nucleic acids or entire genomes can be sequenced by degradation into short overlapping fragments, > 17 bp in length, which can then be sequenced and the total genome sequence can thence be reconstructed using software to determine contig overlaps.

Preparing a Nucleic Acid for Sequencing:

To sequence a complete nucleic acid of significant size is practically very difficult. This process requires fragmentation of the target nucleic acid and sorting into sub-populations that are small enough to allow simultaneous sequencing. Various embodiments of the sorting process have been described previously in the Gene Profiling patent application and the prior sequencing application. Only a minor variation in the use of adaptors to provide distinct termini in a population of generic nucleic acids is discussed here.

Immobilising a specific terminus in a population of nucleic acids:

An important factor is immobilisation of nucleic acids at one terminus. This requires that an arbitrarily generated fragment have directionality, i.e. it requires two distinguishable termini. This can be achieved using adaptors. Two types of adaptors are required to identify two distinct termini. Exemplary adaptors are shown in the attached figures. Adaptor 1 provides immobilisation and the recognition site for a type II restriction endonuclease that generates blunt-ended fragments, in this example the enzyme chosen is BsuRI which is methylation sensitive. DNA to be sequenced would be synthesised with 5-methyl cytosine while adaptors would be synthesised with unmethylated cytosine so that only adaptors would be sensitive to cleavage by BsuRI. Adaptor 2 provides a type II's restriction endonuclease recognition site or alternatively a restriction sight for a second ordinary type II restriction endonuclease.

The adaptors need to be attached to the nucleic acid fragments. Effecting attachment depends on the means used to fragment the population, but assuming random fragmentation with some form of nuclease that generates known sticky-ends, ligation of forms of both adaptor types bearing complementary sequences will be effective or blunt-ended adaptors could be used as shown in Figure 3. This generates fragments of three types: fragments with both ends carrying adaptor 1, fragments with both ends carrying

(9)

adaptor 2 and thirdly fragments carrying adaptor 1 at one end and adaptor 2 at the other. Statistically the third type of fragment will be in the majority. If the immobilisation effector on adaptor 1 is biotin then the fragments carrying adaptor 1 can be immobilised on a solid phase matrix derivitised with avidin. The fragments carrying adaptor 2 at both ends can be washed away. Those fragments carrying two immobilisation adaptors might be immobilised at both termini depending on the fragment lengths. Cleavage with the type II restriction endonuclease whose binding site is carried by adaptor 2 will generate ambiguous sticky-ends at one terminus of the fragments bearing both types of adaptor. The fragments bearing two type 1 adaptors will be unchanged. The cleaved adaptor fragments can then be washed away with the type II restriction endonuclease. A second cleavage with the ordinary type II restriction endonuclease whose cleavage site is in adaptor 1 will release the remaining immobilised fragments that bore one copy of each adaptor at their termini. Those fragments should have an ambiguous sticky-end at the terminus that bore adaptor two and can thus be sorted as described below. Those fragments that carried two copies of adaptor 1 will have blunt-ended termini and will not bind the array and can thus be washed away. In this way a population of nucleic acid fragments can be specifically immobilised at one terminus with the other terminus prepared for sequencing. As long as multiple copies of each sequence is present then statistically the vast majority of sequences should be represented in the portion of the population carrying both adaptors and thus every sequence should be sequenced at least once. Any gaps should become apparent in the contig reconstruction process and can then be specifically searched for using primers targeted at sequences flanking the gaps.

Alternatively sorting can be left until a later step if adaptor 2 bore a cleavage site for an ordinary type II restriction endonuclease that generated a known sticky-end. Preferably a methylation sensitive restriction enzyme would be required to do

66666-THREE

this. The resultant fragments can then be immobilised on beads for further processing such as further amplification or in order to render the fragments single-stranded. One skilled in the art could almost certainly think of other methods of achieving distinct termini. Furthermore, if a restriction map for the target DNA is known then designing adaptors or protocols to distinguish the termini of fragments is simpler.

Generating single-stranded DNA for primer extension sequencing:

This sequencing system requires single-stranded DNA fragments to operate on. This is relatively trivial to generate. One need only use beads derivitised with a double-stranded oligonucleotide that has no terminal phosphate groups on its exposed 5' strand. Cleavage of the DNA fragments to be sequenced with an enzyme that leaves 5' phosphates or use of a kinase to generate 5' phosphate groups on these fragments is required so that ligation of these fragments to the beads can take place, see Figure 4. The ligation will leave the strand linked to the 5' terminus of the immobilised oligonucleotide with a nick. Raising the temperature or otherwise producing denaturing conditions will remove the nicked strand, leaving an immobilised single stranded DNA.

DNA from phage M13 is single-stranded and this is often used as a sequencing vector to generate single-stranded templates for Sanger sequencing.

Sorting molecules into subsets:

Once a fragment population has been amplified and distinct termini established for each fragment, as described above the fragments with ambiguous sticky-ends can be sorted. Sorting can be effected in the same way as described in the Gene Profiling application GB 9618544.2 using beads derivitised with oligonucleotides complementary to the possible sticky-ends that might be generated. The sorting process can be repeated with the first sorted populations using adaptors to provide another

(11)

terminal type IIs restriction endonuclease site. This will allow another set of ambiguous sticky-ends to be generated allowing further sub-sorting until the nucleic acid fragment population is of the correct size for unambiguous sequence determination.

One can effect also sorting with oligonucleotides chips, allowing simultaneous analysis of fragments. This is particularly desirable as the quantities of reagents required would be much smaller than for a series of wells. This sorting method is compatible with fluorescence as a means of detection. A population of DNA fragments with an ambiguous sticky-end at one terminus can be sorted on an oligonucleotide chip by ligation of the exposed sticky-end to its complement. Thus for a 4 bp sticky-end, a chip with the 256 possible 4-mers present at discrete locations on its surface would be required.

This sorting process above generates, for a 4 bp ambiguous sticky-end, 256 sub-populations. This may generate nucleic acid populations small enough to begin sequencing or further sub-sorting may be necessary.

Primer Extension and Parallel Sequencing of Heterogenous Populations of Nucleic Acid Fragments:

Sequencing a single molecule by ligation of single stranded oligonucleotides to a primer:

This process can be understood first by explaining it for the case of a single nucleic acid. Consider a single nucleic acid, immobilised at one terminus to a fixed insoluble matrix. This molecule is rendered single stranded, except for a short stretch of double-stranded DNA at the immobilised terminus of the molecule. This primer sequence could be provided by the adaptor used to immobilise the terminus.

To determine the sequence of this single-stranded molecule one can probe the immobilised nucleic acid with every one of the

554464-00000

(12)

possible 256 single-stranded 4 base oligonucleotides. Each of these would carry a unique identifying label corresponding to its known, sequence of 4 bp. In the 5' to 3' format (see Figures 2a and b), the label could be attached to the 3' -OH effectively blocking them from further extension, or a separate blocking group can be used and the label can be attached elsewhere in the molecule. In the 3' to 5' format (see Figures 1a and b) there is no particular advantage in attaching the mass label to any particular part of the probe, except that it is less likely to interfere with the ligase if it is added to the terminus of the probe.

If the oligonucleotides are added in the presence of a ligase, the oligonucleotide complementary to the 4 bases of sequence adjacent to the primed double-stranded region, will be ligated to the primer. The immobilised matrix can then be washed to remove any unbound oligonucleotides. To determine the sequence of the 4 base oligonucleotide that ligated to the primer, one need only analyse the label attached to the 3' end of the oligonucleotide. The labelling system for use with this invention is described in a PCT patent application filed concurrently with the present application (Page White & Farrer Ref: 86359). This describes 'mass labelling' in which the mass of the label identifies its carrier. Such labels can be made photolabile or cleavable by a specific agent. Cleavage of the label will release it into solution in which it can be injected into an electrospray mass spectrometer for analysis, which will determine the sequence of the oligonucleotide and furthermore, its quantity.

In the preferred embodiment, a photolysable linker would connect the mass label to the 3'-OH which when cleaved would regenerate the 3'-OH with as high an efficiency as possible. The primer has then been extended by 4 known bases and the cycle can be repeated to determine the next 4 bp of sequence. This process can be repeated iteratively until the entire molecule has been

09341641 000000

(13)

sequenced.

An alternative implementation to using photolysable mass labels at the 3'-OH of each 4-mer oligonucleotide would be to cap the 3'-OH with a phosphate group. The mass-label could be attached to another part of the molecule from which it can be released independently of the uncapping reaction of the 3' terminus. Uncapping of the 3' terminus can be effected by washing the immobilised DNA with alkaline phosphatase which will readily remove the capping phosphate from the 3'-OH leaving it available for the next cycle of the sequencing process.

Conceivably this system could be implemented with other labelling schemes, but most other labelling schemes do not generate sufficient, unique labels to be practical. Using fluorescence the same system could be implemented, but since only 4 good dyes are commercially available, the 4 bp oligonucleotides would have to be tested in 64 groups of 4, rather than all at once. Similar considerations apply to use of radiolabels, but here, each oligo would be added one at a time. Other labels include carbohydrates, biotin amongst others.

Actually mass-labelled oligonucleotides would probably be added in two sets of 128 such that each member in the first set would have its complement in the other set. This overcomes the problem of cross-hybridisation between complementary 4-mers.

Sequencing a Population of Nucleic Acid Fragments:

The same process can be applied to a heterogeneous population of immobilised nucleic acids allowing them to be analysed in parallel. To be successful when applied to a population of nucleic acids, this method relies on the assumption that statistically 1 out of 256 molecules within the total population will carry each of the possible 4 bp sequences adjacent to the double stranded primer region. If one sub-sorts one's nucleic acid population into manageable subsets of less than 256

09344644-000000

(14)

fragments, one would expect that almost all will have different ambiguous sticky-ends (there is about a 1 in 1000 chance of there being 2 distinct DNAs having the same 4 bp sequence at any given point if 100 distinct sequences are analysed simultaneously) so for most purposes one can assume that a hybridisation signal corresponds to a single DNA type. This all assumes that DNA sequences are random sequences of bases which is not strictly true but is a sufficient assumption for the purposes of this invention. Obviously 1 in a 1000 is not a small probability and sequences will often have the same 4-mer in a sequencing cycle. However this invention includes an algorithm that can resolve to a great extent any possible ambiguities caused by this occurrence.

Reconstructing Sequences of Target Nucleic Acids:

Repetitions of the primer extension cycle will generate a matrix of quantities of label corresponding to each possible probe. Shown below is a possible matrix for all probes of 4 base pairs in length:

Sequence to which label corresponds	Cycle 1	Cycle 2	Cycle 3	Cycle 4
AAAA	5	24	13	7
AAAC	10	5	9	13
AAAG	13	9	15	17
.....
TTTG	7	13	17	10
TTTT	17	10	7	14

To reconstruct the sequences to which these quantities of label correspond, this invention may incorporate an algorithm for analysing such a data matrix. Such an algorithm and a computer program for employing the algorithm are described in detail in PCT/GB97/02734. The algorithm attempts to identify a sequence

666060" T944E60

(15)

on the basis of its frequency, i.e. a sequence present at a given frequency will have every subsequence present at the same frequency. The algorithm searches through each column of the matrix and attempts to resolve label quantities, that may be sums of sequence frequencies into atomic quantities such that the same set of atomic quantities appear in all columns. The algorithm achieves this by comparing label quantities in a given column with those in the previous and the subsequent columns, except in the case of the first and last columns which can only be compared with the following and previous columns respectively. A given atomic quantity that appears in all columns is then assumed to correspond to a unique sequence.

If two sequences have the same n-mer at a particular point in the sequence, these can be resolved by the quantitative nature of this system in that the quantity of a particular n-mer in a particular ligation will be the sum of the quantities of the two sequences that share the n-mer at the same point. These can be largely resolved by comparison of one cycle with previous and subsequent ligation cycles to identify such sums. This is made particularly simple if the sequences that are being analysed have been amplified by PCR such that the sequence in the lowest quantity is present at not less than half the quantity of the sequence with the greatest frequency, that is to say if the frequency range of sequences lies between some quantity N and $2N$. This means that any sum of frequencies will be greater than $2N$ and hence readily detectable.

There may be occasional ambiguities that only give partial resolution of the sequences. Further resolution can be obtained by performing the same sequencing process for each sample twice. In each case the length of the probe is different, so for the the first sequencing attempt, probes of 4 base pairs would be used and for the second, probes of 5 base pairs would be used. Comparison of the two matrices will allow the sequences to be resolved with far fewer ambiguities.

034464 090909

(16)

Implementation of the invention:

Practical details of implementing the process are described below.

Adaptors, PCR Primers and Oligonucleotides:

Construction of Oligonucleotides, Adaptors, Primers, etc:

Details and reviews on the construction of oligonucleotides are available in numerous up to date texts, which should allow one skilled in the art to construct primers, adaptors and any other oligonucleotides required by the invention:

- Gait, M.J. editor, 'Oligonucleotide Synthesis: A Practical Approach', IRL Press, Oxford, 1990
- Eckstein, editor, 'Oligonucleotides and Analogues: A Practical Approach', IRL Press, Oxford, 1991
- Kricka, editor, 'Nonisotropic DNA Probe Techniques', Academic Press, San Diego, 1992
- Haugland, 'Handbook of Fluorescent Probes and Research Chemicals', Molecular Probes, Inc., Eugene, 1992
- Keller and Manack, 'DNA Probes, 2nd Edition', Stockton Press, New York, 1993
- Kessler, editor, 'Nonradioactive Labeling and Detection of Biomolecules', Springer-Verlag, Berlin, 1992.

Of particular importance is the chemistry used to cap the 3'-OH of the probe oligonucleotides. Acid labile and base labile groups are well known and discussed in the texts above. Capping with a phosphate group is also possible using the above texts, such a group can then be controllably removed using a phosphatase such as alkaline phosphatase which is readily available.

Conditions for Using Oligonucleotide Constructs:

Details on effects of hybridisation conditions for nucleic acid

(17)

probes can be found in be found in references below:

- Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26, 227-259, 1991
- Sambrook et al, 'Molecular Cloning: A Laboratory Manual, 2nd Edition', Cold Spring Harbour Laboratory, New York, 1989
- Hames, B.D., Higgins, S.J., 'Nucleic Acid Hybridisation: A Practical Approach', IRL Press, Oxford, 1988

Ligation:

Ligation of oligonucleotides is a critical aspect of the invention that must be considered. Chemical methods of ligation are known:

- Ferris et al, Nucleosides and Nucleotides_8, 407 - 414, 1989
- Shabarova et al, Nucleic Acids Research 19, 4247 - 4251, 1991

Preferably enzymatic ligation would be used as this has much higher fidelity. Preferred ligases would be T4 DNA ligase, T7 DNA ligase, E. coli DNA ligase, Taq ligase, Pfu ligase and Tth ligase. References to the literature are given below:

- Lehman, Science 186, 790 - 797, 1974
- Engler et al, 'DNA Ligases', pg 3 - 30 in Boyer, editor, 'The Enzymes, Vol 15B', Academic Press, New York, 1982

Protocols for use of ligases can be found in:

- Sambrook et al, cited above
- Barany, PCR Methods and Applications, 1: 5 - 16, 1991
- Marsh et al, Strategies 5, 73 - 76, 1992

Phosphorylation of Nucleic Acids:

66000-1497460

(18)

When ligases and restriction endonucleases are used, there are changes made to the 5' phosphates of nucleic acid backbone sugar molecules. It is critical to this invention that extension of primers by ligated oligonucleotides be tightly controlled such that only one oligonucleotide is ligated to each extending primer in each cycle of the sequencing process. It is also possible to alter the phosphorylation state of oligonucleotides, adaptors or target nucleic acids during their synthesis or later, in versions of the process. Included are references to literature regarding use of phosphatases, kinases and chemical methods:

- Horn and Urdea, Tetrahedron Lett. 27, 4705, 1986
- Sambrook et al, cited above

The 5'-hydroxyl gp of the oligonucleotides can be chemically phosd. by means of phosphoryl chloride (POCl_3).

Restriction Endonucleases:

Numerous type II and IIs restriction endonucleases exist and could be used with this invention. Table 1 below gives a list of examples but is by no means comprehensive. A literary review of restriction endonucleases can be found in Roberts, R., J. Nucl. Acids Res. 18, 2351 - 2365, 1988. New enzymes are discovered at an increasing rate and more up to date listings are recorded in specialist databases such as REBase which is readily accessible on the internet using software packages such as Netscape or Mosaic and is found at the World Wide Web address: <http://www.neb.com/rebase/>. REBase lists all restriction enzymes as they are discovered and is updated regularly, moreover it lists recognition sequences, isoschizomers of each enzyme, manufacturers and suppliers and references to them in scientific literature. The protocol would be much the same irrespective of the type IIs restriction endonuclease used but the spacing of recognition sites for a given enzyme within an adaptor would be tailored according to requirements and the enzymes cutting behaviour. (see figure n above)

(19)

Enzyme Name	Recognition sequence	Cutting site
FokI	GGATG	9/13
BstF51	GGATG	2/0
SfaNI	GCATC	5/9
HgaI	GACGC	5/10
BbvI	GCAGC	8/12

Table 1: A sample of type IIs restriction endonucleases

The requirement of the process is the generation of ambiguous sticky-ends at the termini of the nucleic acids being analysed. This could also be achieved by controlled use of 5' to 3' exonucleases. Clearly any method that achieves the creation of such sticky-ends will suffice for the process.

Similarly ordinary type II restriction endonucleases required by this invention can be found in the reference sources listed above. Details on methylation sensitivity and other means of controlling enzyme action can be found in the references given in REBase or can be acquired from the manufacturers.

Solid Phase Supports:

A full discussion of solid phase supports can be found in Brenner PCT/US95/12678 pg 12 - 14. This is an important issue in the use of fluorimetry to determine sequence abundance in that the design of supports will affect the acquisition of fluorescent signals which must be maximised for this process to be effective.

Mass Spectrometry of labels on oligonucleotides:

Electrospray mass spectrometry is the preferred technique for identification of labels attached to oligonucleotides since it is a very soft technique and can be directly coupled to the

656060" F4974E50

liquid phase molecular biology used in this invention. For a full discussion of mass spectrometry techniques see:

- R.A.W. Johnstone and M.E. Rose, "Mass Spectrometry for chemists and biochemists" 2nd edition, Cambridge University Press, 1996.

Mass labels:

For any practically or commercially useful system it is important that construction of labels be as simple as possible using as few reagents and processing steps as possible. A combinatorial approach in which a series of monomeric molecular units are available to be used in multiple combinations with each other

Amino acids:

With a small number of amino acids such as glycine, alanine and leucine, a large number of small peptides with different masses can be generated using standard peptide synthesis techniques well known in the art. With more amino acids many more labels can be synthesised.

- E. Atherton and R.C. Sheppard, editors, 'Solid Phase Peptide Synthesis: A Practical Approach', IRL Press, Oxford.

Carbohydrates:

Similarly carbohydrate molecules are useful monomeric units that can be synthesised into heteropolymers of differing masses but these are not especially amenable to ESMS.

- Gait, M.J. editor, 'Oligonucleotide Synthesis: A Practical Approach', IRL Press, Oxford, 1990
- Eckstein, editor, 'Oligonucleotides and Analogues: A Practical Approach', IRL Press, Oxford, 1991

Other labelling chemistries:

Clearly almost any molecule can be tacked onto another as a label. Obviously the properties of such labels in the mass-spectrometer will vary. In terms of analysing biomolecules it will be important that the labels be inert, etc, as discussed previously. Cholesterol groups and glyceryl groups are possibilities that could be used but these are intrinsically relatively large molecules and the scope.

Designing molecules with favorable mass-spectrometry purposes:

One can synthesis labels using standard organic chemistry techniques. Such labels ought to carry amine derivatives, quaternary ammonium ions or positive sulphur centres if positive ions are sought. These have extremely good detection properties that generate clean sharp signals. Similarly, negatively charged ions can be used, so molecules with carboxylate moieties can be used. Labels for MALDI mass spectrometry can be generated by derivitising known molecules that are excitable by UV laser light, such as sinapinnic acid or cinnamic acid, of which a number of derivatives are already commercially available. For a text on organic chemistry see:

- Vogel's "Textbook of Organic Chemistry" 4th Edition, Revised by B.S. Furniss, A.J. Hannaford, V. Rogers, P.W.G. Smith & A.R. Tatchell, Longman, 1978.

Linkers:

An important feature of this invention is attachment of labels to their relevant biomolecules and in the 5' to 3' sequencing embodiment, the need for removable blocking groups is also critical. For details on these issues see:

- Theodora W. Greene, "Protective Groups in Organic Synthesis", 1981, Wiley-Interscience

Fluorimetry:

Certain embodiments of the process could use oligonucleotides

(22)

bearing fluorescent labels. Detection of fluorescent signals can be performed using optical equipment that is readily available. Fluorescent labels usually have optimum frequencies for excitation and then fluoresce at specific wavelengths in returning from an excited state to a ground state. Excitation can be performed with lasers at specific frequencies and fluorescence detected using collection lenses, beam splitters and signal distribution optics. These direct fluorescent signals to photomultiplier systems which convert optical signals to electronic signals which can be interpreted using appropriate electronics systems.

Brenner PCT/US95/12678 pg 26 - 28 gives a full discussion.

Liquid Handling Robotics:

For this process to be practically useful, automation is essential and liquid handling robots can be acquired from various sources such as Applied Biosystems.

Example-Sequencing by the ligation of 4-mers

An experiment was carried out involving the extension of a sequencing primer, hybridised to a single stranded DNA template, by the stepwise ligation of 4mers. In general the 4mers will contain labels with which the sequence of the 4mer and hence the template can be derived. 256 4mers are required to cover all possible variations. Each 4mer must contain a blocking group, preferably the identifying label, at the 3'hydroxyl to ensure that only one 4mer is ligated to the sequencing primer with each cycle. After successful ligation the blocking group (and the label if different) is removed by chemical or other means to expose the 3'hydroxyl of the 4mer. The label, and hence the sequence, is then identified. The 4mer is then available for the ligation of the next 4mer in the second cycle.

In order to demonstrate the effectiveness of removing of the 3'blocking group of the ligated 4mer a non-blocked 4mer was

(23)

ligated to the sequencing primer in a separate reaction and this was then used as a template for the next cycle. The Experiment is depicted in schematic form below:

Sequencing template - captured to streptavidin coated plate via a biotin molecule (B):

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

Cycle 1

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

+

5' PO4-TGTC-3' FAM, 5' PO4-TACT-3' FAM, 5' PO4-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-FAM

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

Only 5' PO4-TGTC-3' FAM ligates to give a signal which identifies the first 4 bases ('3ACAG'5) of the template.

To simulate the deprotection of the above species the following reaction was carried out:

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TGTC-3' OH

=

5' CTGGTACGTACATACGACTA-TGTC-3' OH

09341641-090999

(24)

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

The above species was then used as a template for Cycle 2.

Cycle 2

5' CTGGTACGTACATACGACTA-TGTC-3' OH

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO₄-TGTC-3' FAM, 5' PO₄-TACT-3' FAM, 5' PO₄-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-FAM

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

Only 5' PO₄-TACT-3' FAM ligates to give a signal which identifies the next 4 bases (3ATGA'5) of the template.

Also to simulate the deprotection of the above species the following reaction was carried out:

5' CTGGTACGTACATACGACTA-TGTC-3' OH

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO₄-TACT-3' OH,

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-OH

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

The above species was then used as a template for Cycle 3.

556060" T9T4E60

(25)

Cycle 3

5' CTGGTACGTACATACGACTA-TGTC-TACT-OH

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TGTC-3' FAM, 5' PO4-TACA-3' FAM, 5' PO4-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-TACA-FAM

3' GACCATGCATGTATGCTGAT-ACAG-ATGA-ATGTATTTGAT (N) 14-5' B

Only 5' PO4-TACA-3' FAM ligates to give a signal which identifies the next 4 bases (3ATGT'5) of the template.

Therefore, through 3 cycles of ligation of 4mers the sequence ACAGATGAATGT of the template was deduced.

Materials:

Oligonucleotides:

sequencing primer

5' CTGGTACGTACATACGACTA' 3OH

sequencing template (contains a 5' biotin molecule)

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

4mers used

0344-0999
666060 "TheFEE"

(26)

5' PO4-TGTC-3' FAM, 5' PO4-TACT-3' FAM, 5' PO4-TAGA-FAM,
5' PO4-TACA-FAM, 5' PO4-TGTC-3' OH, 5' PO4-TACT-3' OH

All oligos were synthesised by Oswel DNA (UK).

Solutions:

wash solution 50mM Tris-HCl pH7.6
 10mM MgCl₂

binding solution 50mM Tris-HCl pH7.6
 10mM MgCl₂
 1M NaCl

ligase buffer 50mM Tris-HCl pH7.6
 10mM MgCl₂
 10mM DTT
 1mM ATP
 50ug/ml BSA

Methods:

Hybridisation of the sequencing primer to the template

Aliquots with 500ul of 0.5 times binding solution containing 5pmol/ul of each of the sequencing primer and template were heated at 95oC for 5 mins and then allowed to cool to room temperature over 2 hours. They were then incubated at 4oC for 1 hour and frozen at -20oC until used.

This will now be referred to as 'the sequencing template'.

(27)

Capture of the Sequencing Template

20pmol (4ul) + 21ul of binding solution was added to each well of a black streptavidin coated 96 well microtitre plate (Boehringer Mannheim) and incubated at room temperature for 1 hour. The wells were then washed twice with 200ul of wash solution and once with 50ul of ligase buffer. The plates were then stored at 4oC until used.

Cycle 1

Three groups of reactions, one group with a specific 4mer (TGTC) and two with non-specific 4mers (TACT and TAAA) were set up as follows.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO4-TGTC3'-FAM, 5'PO4-TACT3'-FAM and 5'PO4-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way, but without the inclusion of the ligase to control for non-specific binding of the 4mers.

To simulate a deprotected, successfully ligated 4mer to the sequencing template 48 reactions containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 5'PO4-TGTC3'OH in 25 ul of ligase buffer were set up.

The above reactions were then added to wells of the microtitre plate containing the sequencing template and incubated at 4oC for 30 minutes followed by 16oC for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well. The amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent

(28)

microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 1

The following data for Cycle 1 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	10764	10878	120119
	9815	9994	97638
	11635	12543	98891
	12031	11188	95931
mean	11069	11151	103145

The following data from Cycle 1 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	14605	13987	15134
	13638	13692	15370
	13938	14823	16019
	13826	13117	17849
mean	14002	13905	16093

These data clearly show that TGTC-FAM has been specifically ligated to the sequencing template. The other 4mers, in the

(29)

presence of ligase, gave signals similar to those obtained from non-specific hybridisation control reactions.

Therefore, this specific signal provides the first 4 bases (3'ACAG5') of the sequencing template.

Cycle 2

The following reactions were applied to the sequencing template to which the specific 5'PO4-TGTC-3'OH 4mer had been ligated (as described in Cycle 1) to mimic a 4mer which had been deprotected/identified.

Three groups of reactions, one group with a specific 4mer (TACT) and two with non-specific 4mers (TGTC and TAAA) were set up as follows.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO4-TGTC3'-FAM, 5'PO4-TACT3'-FAM and 5'PO4-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way but without the inclusion of the ligase to control for non-specific binding of the 4mers.

To simulate a deprotected, successfully ligated 4mer to the sequencing template 24 reactions containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 5'PO4-TACT3'OH in 25 ul of ligase buffer were set up.

The above reactions were then added to wells of the microtitre plate containing the sequencing template, with 5'PO4-TGTC-3'OH

(30)

ligated to it as described in cycle 1, and incubated at 40C for 30 minutes followed by 160C for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well the amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 2

The following data for Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	9238	24071	9693
	8207	24455	9415
	10312	23194	11071
	9153	21641	10815
mean	9227	23340	10248

The following data from Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

TAAA-FAM	TACT-FAM	TGTC-FAM
12532	16025	13917
11947	15651	13573
12040	17587	13049

	11908	16464	12998
mean	12107	16432	13384

Therefore cycle 2 has produced the next 4 bases (3'ATGA5') of the sequencing template.

The following reactions were applied the sequencing template to which the specific 5'PO₄-TACT-3'OH 4mer had been ligated (as described in Cycle 2) to mimic a 4mer which had been deprotected/identified.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO4-TGTC3'-FAM, 5'PO4-TACT3'-FAM and 5'PO4-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way, but without the inclusion of the ligase to control for non-specific binding of the 4mers.

The above reactions were then added to wells of the microtitre plate containing the sequencing template, with 5'PO₄-TACT-3'OH

(32)

ligated to it as described in cycle 2, and incubated at 40C for 30 minutes followed by 160C for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well the amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 3

The following data for Cycle 3 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACA-FAM	TGTC-FAM
	8294	61002	10307
	8136	52253	9659
	10323	53848	11894
	9424	51570	12443
mean	9044	54668	11076

The following data from Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

TAAA-FAM	TACA-FAM	TGTC-FAM
11605	16641	14000
11417	15414	14704
11995	17719	14443

(33)

	11959	16021	14381
mean	11744	16449	14382

As with Cycles 1 and 2, Cycle 3 produces a clear signal from the specific 4mer ligation as compared to the non-specific 4mer ligations and the non-specific hybridisation control reactions which lacked ligase.

Therefore cycle 3 produced the next 4 bases (3'ATGT5') of the sequencing template.

A total of 12 bases (3'ACAGATGAATGT5') were successfully sequenced by three rounds of ligations using a fluorescent system which does not require the use of gel electrophoresis.

The specific 4mers (e.g. TACA in Cycle 3) generally give a slightly higher reading in the non-specific hybridisation reactions, without ligase, compared to the non-specific 4mers. This is due to the fact that they are hybridising to their specific target on the sequencing template and are not being fully removed in the washing steps. These slightly higher signals could be reduced to the levels of the non-specific 4mers by increasing the stringency of the washing steps by lowering the ionic strength or increasing the temperature of the wash solution.

The signals obtained for the reactions with ligase of the mis-matched 4mers are lower than those obtained from the non-specific hybridisation control reactions. This is probably due to the presence of a substance in the ligase solution, which is not being removed by the washing steps, quenching some of the fluorescence. This difference could be removed by improving the

96060" T9T+EE9

(34)

washing steps or by including inactivated ligase solution into these reactions thereby insuring the same amount of quenching in all reactions.

To ensure that the maximum possible number of cycles may be carried out using this method, it is important to ensure that the ligation efficiency is very high for each step, so that sufficient template is produced for the next cycle.

E66060-7437460

CLAIMS:

1. A method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising a plurality of single-stranded DNAs to be sequenced, each of which is present in a unique amount in the same reaction zone and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of each single-stranded DNA by determining the sequence of release of each label.

2. A method according to claim 1, wherein the array comprises a plurality of sub-arrays which together contain all the possible

base sequences, and wherein each sub-array is contacted with the DNA population according to step (b), unligated probes are removed according to step (c), and these steps are repeated in a cycle before step (d) so that all of the sub-arrays contact the DNA population.

3. A method according to claim 1 or claim 2, wherein the target DNA population is obtained by sorting an initial DNA sample into sub-populations and selecting one of the sub-populations as the target DNA population.

4. A method according to claim 3, wherein the initial DNA sample is cut into fragments, each having a sticky end of known length and unknown sequence, which fragments are sorted into sub-populations according to their sticky end sequence.

5. A method according to any one of the preceding claims, wherein each single-stranded DNA is immobilised at one end.

6. A method according to any one of the preceding claims, wherein the label of each probe comprises a mass label, and the quantity of each label is recorded according to step (e) using mass spectrometry after release of the label in step (d).

7. A method according to any one of the preceding claims, wherein the known base sequence is blocked at its 3'OH.

8. A method according to claim 7, wherein the step (d) of cleaving the ligated probes to release each label unblocks the 3'-OH of the extended double-stranded portion according to step (f).

66660" T9T4E60

(37)

9. A method according to claim 8, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence.
10. A method according to any one of claims 1 to 6, wherein the base sequence of each probe is unphosphorylated at both 3' and 5' ends and step (f) comprises phosphorylating the 5'-OH of the extended double-stranded portion.
11. A method according to any one of the preceding claims, wherein the predetermined length of the base sequence is from 2 to 6.
12. A method according to claim 11, wherein the predetermined length of the base sequence is 4.
13. A kit for sequencing DNA, which comprises an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligating to each other.
14. A kit according to claim 13, wherein the known base sequence is blocked at its 3'-OH.
15. A kit according to claim 14, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence to prevent ligation thereto.
16. A kit according to any one of claims 13 to 15, wherein the base sequence of each probe is unphosphorylated at both 3' and

094644-0099

17. A kit according to any one of claims 13 to 16, wherein the label of each probe comprises a mass label.

18. A kit according to any one of claims 13 to 17, wherein the predetermined length of the base sequence is from 2 to 6.

19. A kit according to claim 18, wherein the predetermined length of the base sequence is 4.

20. Use of a kit according to any one of claims 13 to 19 for a method of sequencing DNA.




FIG. 1A






FIG. 1B


CYCLE 1:

DNA PREPARED BY VARIOUS
MEANS FROM ANY SOURCE

STEP 1



ADD ALL 256 POSSIBLE 4-MERS IN THE
PRESENCE OF A LIGASE, TO EXTEND
DOUBLE-STRANDED PRIMER REGION
BY 4 BASE PAIRS. THE LIGASE ACTS TO
ENSURE THE FIDELITY OF THE
EXTENSION



STEP 2

WASH IN LOW STRINGENCY BUFFER
OR RAISE TEMPERATURE OF MEDIUM
TO REMOVE ANY UNLIGATED 4-MERS



STEP 3

CLEAVE MASS-LABEL BY PHOTOLYSIS
OR CHEMICAL CLEAVAGE AND REMOVE
SUPERNATANT FOR ANALYSIS IN MASS
SPECTROMETER. CLEAVAGE LEAVES
3'-OH AVAILABLE FOR FURTHER
EXTENSION




FIG. 2A




FIG. 2B






FIG. 3


ADAPTORS TO GENERATE DISTINCT
TERMINI IN GENERIC NUCLEIC ACIDS

DNA CLEAVED WITH A RESTRICTION
ENZYME LIKE BamHI




ADD BEADS BEARING A DOUBLE-STRANDED
OLIGONUCLEOTIDE WITH A STICKY-END
COMPLEMENTARY TO RESTRICTION
ENZYME STICKY-ENDS BUT WITH NO
TERMINAL PHOSPHATE GROUPS

NICK REMAINS



THERMALLY DENATURE STRANDS SO
NICKED STRAND IS RELEASED WASH THE
FREE DNA AWAY



SINGLE-STRANDED PRIMED DNA REMAINS



DIAGRAM TO SHOW PREPARATION OF
SINGLE-STRANDED DNA FOR PRIMER
EXTENSION SEQUENCING.

FIG. 4




FIG. 5




FIG. 6




FIG. 7

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to Provisional and PCT International Applications)

ATTORNEY'S DOCKET NUMBER

020600-280

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NUCLEIC ACID SEQUENCING

the specification of which (check only one item below):

☐ is attached hereto.

☒ was filed as United States application

Number 09/341,641

on July 15, 1999

and was amended

on _____ (if applicable).

☒ was filed as PCT international application

Number PCT/GB98/00130

on January 15, 1998

and was amended

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
GB	9700760.3	15 January 1997	<u>X</u> Yes ___ No
			___ Yes ___ No
			___ Yes ___ No
			___ Yes ___ No
			___ Yes ___ No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)			ATTORNEY'S DOCKET NO. 020600-280																																																																																						
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>																																																																																									
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:																																																																																									
U.S. APPLICATIONS			STATUS (check one)																																																																																						
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED																																																																																					
PCT APPLICATIONS DESIGNATING THE U.S.																																																																																									
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)																																																																																							
<p>I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 33%;">William L. Mathis</td> <td style="width: 10%; text-align: right;">17,337</td> <td style="width: 33%;">R. Danny Huntington</td> <td style="width: 10%; text-align: right;">27,903</td> <td style="width: 33%;">Gerald F. Swiss</td> <td style="width: 10%; text-align: right;">30,113</td> </tr> <tr> <td>Robert S. Swecker</td> <td style="text-align: right;">19,885</td> <td>Eric H. Weisblatt</td> <td style="text-align: right;">30,505</td> <td>Michael J. Ure</td> <td style="text-align: right;">33,089</td> </tr> <tr> <td>Platon N. Mandros</td> <td style="text-align: right;">22,124</td> <td>James W. Peterson</td> <td style="text-align: right;">26,057</td> <td>Charles F. Wieland III</td> <td style="text-align: right;">33,096</td> </tr> <tr> <td>Benton S. Duffett, Jr.</td> <td style="text-align: right;">22,030</td> <td>Teresa Stanek Rea</td> <td style="text-align: right;">30,427</td> <td>Bruce T. Wieder</td> <td style="text-align: right;">33,815</td> </tr> <tr> <td>Norman H. Stepno</td> <td style="text-align: right;">22,716</td> <td>Robert E. Krebs</td> <td style="text-align: right;">25,885</td> <td>Todd R. Walters</td> <td style="text-align: right;">34,040</td> </tr> <tr> <td>Ronald L. Grudziecki</td> <td style="text-align: right;">24,970</td> <td>William C. Rowland</td> <td style="text-align: right;">30,888</td> <td>Ronni S. Jillions</td> <td style="text-align: right;">31,979</td> </tr> <tr> <td>Frederick G. Michaud, Jr.</td> <td style="text-align: right;">26,003</td> <td>T. Gene Dillahunt</td> <td style="text-align: right;">25,423</td> <td>Harold R. Brown III</td> <td style="text-align: right;">36,341</td> </tr> <tr> <td>Alan E. Kopecki</td> <td style="text-align: right;">25,813</td> <td>Patrick C. Keane</td> <td style="text-align: right;">32,858</td> <td>Allen R. Baum</td> <td style="text-align: right;">36,086</td> </tr> <tr> <td>Regis E. Slutter</td> <td style="text-align: right;">26,999</td> <td>Bruce J. Boggs, Jr.</td> <td style="text-align: right;">32,344</td> <td>Steven M. du Bois</td> <td style="text-align: right;">35,023</td> </tr> <tr> <td>Samuel C. Miller, III</td> <td style="text-align: right;">27,360</td> <td>William H. Benz</td> <td style="text-align: right;">25,952</td> <td>Brian P. O'Shaughnessy</td> <td style="text-align: right;">32,747</td> </tr> <tr> <td>Robert G. Mukai</td> <td style="text-align: right;">28,531</td> <td>Peter K. Skiff</td> <td style="text-align: right;">31,917</td> <td></td> <td></td> </tr> <tr> <td>George A. Hovanec, Jr.</td> <td style="text-align: right;">28,223</td> <td>Richard J. McGrath</td> <td style="text-align: right;">29,195</td> <td></td> <td></td> </tr> <tr> <td>James A. LaBarre</td> <td style="text-align: right;">28,632</td> <td>Matthew L. Schneider</td> <td style="text-align: right;">32,814</td> <td></td> <td></td> </tr> <tr> <td>E. Joseph Gess</td> <td style="text-align: right;">28,510</td> <td>Michael G. Savage</td> <td style="text-align: right;">32,596</td> <td></td> <td></td> </tr> </table>						William L. Mathis	17,337	R. Danny Huntington	27,903	Gerald F. Swiss	30,113	Robert S. Swecker	19,885	Eric H. Weisblatt	30,505	Michael J. Ure	33,089	Platon N. Mandros	22,124	James W. Peterson	26,057	Charles F. Wieland III	33,096	Benton S. Duffett, Jr.	22,030	Teresa Stanek Rea	30,427	Bruce T. Wieder	33,815	Norman H. Stepno	22,716	Robert E. Krebs	25,885	Todd R. Walters	34,040	Ronald L. Grudziecki	24,970	William C. Rowland	30,888	Ronni S. Jillions	31,979	Frederick G. Michaud, Jr.	26,003	T. Gene Dillahunt	25,423	Harold R. Brown III	36,341	Alan E. Kopecki	25,813	Patrick C. Keane	32,858	Allen R. Baum	36,086	Regis E. Slutter	26,999	Bruce J. Boggs, Jr.	32,344	Steven M. du Bois	35,023	Samuel C. Miller, III	27,360	William H. Benz	25,952	Brian P. O'Shaughnessy	32,747	Robert G. Mukai	28,531	Peter K. Skiff	31,917			George A. Hovanec, Jr.	28,223	Richard J. McGrath	29,195			James A. LaBarre	28,632	Matthew L. Schneider	32,814			E. Joseph Gess	28,510	Michael G. Savage	32,596		
William L. Mathis	17,337	R. Danny Huntington	27,903	Gerald F. Swiss	30,113																																																																																				
Robert S. Swecker	19,885	Eric H. Weisblatt	30,505	Michael J. Ure	33,089																																																																																				
Platon N. Mandros	22,124	James W. Peterson	26,057	Charles F. Wieland III	33,096																																																																																				
Benton S. Duffett, Jr.	22,030	Teresa Stanek Rea	30,427	Bruce T. Wieder	33,815																																																																																				
Norman H. Stepno	22,716	Robert E. Krebs	25,885	Todd R. Walters	34,040																																																																																				
Ronald L. Grudziecki	24,970	William C. Rowland	30,888	Ronni S. Jillions	31,979																																																																																				
Frederick G. Michaud, Jr.	26,003	T. Gene Dillahunt	25,423	Harold R. Brown III	36,341																																																																																				
Alan E. Kopecki	25,813	Patrick C. Keane	32,858	Allen R. Baum	36,086																																																																																				
Regis E. Slutter	26,999	Bruce J. Boggs, Jr.	32,344	Steven M. du Bois	35,023																																																																																				
Samuel C. Miller, III	27,360	William H. Benz	25,952	Brian P. O'Shaughnessy	32,747																																																																																				
Robert G. Mukai	28,531	Peter K. Skiff	31,917																																																																																						
George A. Hovanec, Jr.	28,223	Richard J. McGrath	29,195																																																																																						
James A. LaBarre	28,632	Matthew L. Schneider	32,814																																																																																						
E. Joseph Gess	28,510	Michael G. Savage	32,596																																																																																						
<p>and: <u>Robin L. Teskin, Reg. No. 35,030</u></p>																																																																																									
<p>Address all correspondence to: <u>Samuel C. Miller, III</u> <u>BURNS, DOANE, SWECKER & MATHIS, L.L.P.</u> <u>P.O. Box 1404--</u> <u>Alexandria, Virginia 22313-1404</u></p>																																																																																									
<p>Address all telephone calls to: <u>Samuel C. Miller, III</u> at (703) 836-6620.</p>																																																																																									
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>																																																																																									

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)		ATTORNEY'S DOCKET NO. 020600-280	
1-01 FULL NAME OF SOLE OR FIRST INVENTOR <u>Gunter Schmidt</u>		SIGNATURE <u>[Signature]</u> DATE <u>27/8/99</u>	
RESIDENCE Houghton Manor, Houghton, Cambridge PE17 2BQ, United Kingdom <u>GAX</u>		CITIZENSHIP German	
POST OFFICE ADDRESS Houghton Manor, Houghton, Cambridge PE17 2BQ, United Kingdom			
2-01 FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>Andrew Hugin Thompson</u>		SIGNATURE <u>[Signature]</u> DATE <u>27/8/99</u>	
RESIDENCE 25 Knoll Park, Alloway, Ayr KA7 4RH, United Kingdom <u>GAX</u>		CITIZENSHIP United Kingdom	
POST OFFICE ADDRESS 25 Knoll Park, Alloway, Ayr KA7 4RH, United Kingdom			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE	
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			